RxDoctor Payments Data

Jiri Brabec, MD

Neurology · Lawrence, MANPI 1093944332

Payments from drug & device makers

$4,215in general payments, 2019–2025

Across 225 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$783
  • Teva Pharmaceuticals USA, Inc.$501
  • Supernus Pharmaceuticals, Inc.$465
  • Novartis$276
  • SK Life Science, Inc.$270
  • Pfizer$244
  • plus $2K from 22 others

What the payments were for

  • Speaking & faculty fees$190%
  • Food & beverage$4,10597%
  • Education$912%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,215 in reported general payments places this provider in the 60th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$103,531
Medicare patients
527
Services billed
1,079

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine18$220,648
Aimovig AutoinjectorErenumab-Aooe251$211,548
Kesimpta PenOfatumumab12$101,846
Nurtec OdtRimegepant Sulfate58$82,778
QuliptaAtogepant64$76,785
CopaxoneGlatiramer Acetate13$74,089
UbrelvyUbrogepant53$67,603
NuplazidPimavanserin Tartrate13$64,443
Ajovy AutoinjectorFremanezumab-Vfrm50$56,514
Emgality PenGalcanezumab-Gnlm68$48,996
NourianzIstradefylline21$47,078
RytaryCarbidopa/Levodopa32$32,839
XcopriCenobamate26$32,056
BotoxOnabotulinumtoxina25$30,489
BriviactBrivaracetam16$25,008

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr, Copaxone$501$294,73731 claims
AbbVieQulipta, Ubrelvy, Botox$783$174,877142 claims
PfizerNurtec Odt$244$82,77858 claims
Acadia Pharmaceuticals IncNuplazid$23$64,44313 claims
Kyowa Kirin, Inc.Nourianz$82$47,07821 claims
UCB, Inc.Briviact, Neupro$115$46,43431 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$178$35,35658 claims
SK Life Science, Inc.Xcopri$270$32,05626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 761 neurology providers in Massachusetts.

Other neurology in Lawrence

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →